ライフサイエンスコーパス: i.p.

1 i.p. Insl5 increased food intake in wild-type mice but n

2 BALB/c mice were sensitized to OVA (day 0) i.p. and challenged intranasal (12-15 d later) to induce

3 n vitro profile, contilisant (at 1 mg kg(-1) i.p.) also significantly improved lipopolysaccharide-ind

4 ibition via glibenclamide (GLI; 10 mg kg(-1) i.p.) would decrease cardiac output at rest (echocardiog

5 iet and low-dose streptozotocin (25mgkg(-1), i.p.) in rats.

6 nic exposure (7 or 21 days) to WIN 55,212-2 (i.p., 3.7 mg/kg), a potent cannabinoid agonist, on dendr

7 Currently, 3 of 4 i.p./s.c.- and 2 of 4 p.o. secondary passage-inoculated

8 on (15 Gy), we injected small molecule 77427 i.p. approximately 1 hour after radiation then twice wee

9 tested our hypothesis by administering HUP-A i.p. or intrathecally to female Sprague-Dawley rats (200

10 Neutrophils were depleted using anti-Gr1 Ab (i.p. 0.5 mg/mouse/every 3 d).

11 of proinflammatory cytokines following acute i.p. challenge with LPS plus ATP in a manner that is pro

12 , and polystyrene nanoparticles administered i.p. were all found to selectively accumulate in TAMs.

13 Similarly, SB202190 administration (i.p.) abolished UBR2 up-regulation in the tibialis anter

14 After i.p. injection in mice, g-EAR showed gelation in the per

15 After i.p. injection of LPS, lower levels of TNFalpha, IL-6, a

16 g lymph nodes (dLNs) and the spleen 6h after i.p. immunization, as compared to after i.m. immunizatio

17 WT mice with N. menigitidis B-MC58 6 h after i.p. administration of Pn (100 microg/mouse) or buffer a

18 (18 m min(-1) ; 5 degrees grade), 1 h after i.p. administration of rapamycin (1.5 mg . kg(-1) ) or v

19 At 6 h after i.p. LPS injection, transgenic hSR-BI and hSR-BII mice d

20 mplete protection against organ injury after i.p. LPS.

21 induce a CD4(+) T cell IL-17 response after i.p. immunization is associated with T cell priming, as

22 he in vivo PK experiments, 14i showed, after i.p. dosing, encouraging plasma PK profile and brain exp

23 ro (in primary monocytes) and in vivo (after i.p. injection in the mouse).

24 We report that at 2 wk after i.p. or transtracheal delivery of 1 x 10(6) OVA-, but no

25 city and higher therapeutic efficacy against i.p. chemotherapy-resistant uterine serous carcinoma-der

26 In an OVA/Alum i.p.-sensitization mouse model, Amb-APE was intranasally

27 infusion of a Gd-based Zn(II) sensor and an i.p. bolus of glucose.

28 Two hours after CLP, an i.p. injection of 200 mug/kg of anti-rat NPCT antibody w

29 In contrast to an i.p. infectious model, in which IL-12p35, MHCII, and B c

30 hibition in MM tumor growth in both s.c. and i.p. models and the presence of a chemotherapeutic drug,

31 eficiency mice, and tumor growth in s.c. and i.p. models of MM was followed.

32 litaxel was administered i.v. at 50 mg/m and i.p. at 20 mg/m on days 1 and 8.

33 ctive dose) of MARV/Ang-MA in SCID mice, and i.p. infection at a dose of 1,000x LD50 resulted in deat

34 beginning at 3 days p.i. from both i.n.- and i.p.-challenged animals.

35 m from Pneumocystis-infected mice as well as i.p. injection of Pneumocystis into uninfected IFrag(-/-

36 armacological PI3K-gamma inhibitor AS252424 (i.p. 10 mg/kg daily) or genetically using Pi3k-gamma(-/-

37 Treatment of mice with 5-azacytidine (i.p.) resulted in a significant dose-dependent increase

38 sly administered KGF to mice 24 hours before i.p. cyclophosphamide administration, followed by histol

39 macrophages covering FLAgs efficiently bind i.p. injected normal B cells as well as different types

40 d no drug tolerance following repeated bolus i.p. or chronic intrathecal HUP-A dosing.

41 Most importantly, both i.p. and intranasal immunization with these NPs offered

42 in utero elicited after cPAF administered by i.p. or intrauterine routes.

43 alleviated fetal demise in utero elicited by i.p. LPS administration in late gestation.

44 cute necrotizing pancreatitis was induced by i.p. administration of cerulein or by intraductal admini

45 pH unit changes in vivo in tumors induced by i.p. injection of glucose.

46 odel of mild systemic endoxotemia induced by i.p. injection of lipopolysaccharide, we report that JAM

47 at1-knockout (KO) and wild-type (WT) mice by i.p. injection of class II-disparate bm12 splenocytes.

48 ice were administered with METH or saline by i.p. injections for 5 days with an escalating dose regim

49 /c mice were treated with monoclonal anti-C5 i.p. on day 3 or 6 after intragastric inoculation and mo

50 umor efficacy in an ES-2-luc, ovarian cancer i.p. xenograft model.

51 ness behavior following an immune challenge (i.p. lipopolysaccharide [LPS] injection) in mice.

52 competent BALB/c and C57BL/6 mice challenged i.p. with 2,000x LD50 of MARV/Ang-MA.

53 Chronic i.p. treatment of the triple transgenic (APPsw/PS1M146V/

54 e trained to discriminate 10.0 mg/kg CR4056 (i.p.) from vehicle in a two-lever food-reinforced drug d

55 ith murine recombinant 3K3A-APC (100 ug/kg/d i.p.) prevents development of parenchymal and cerebrovas

56 Furthermore, daily i.p. injection of SR3306 (7 days) prevented the increase

57 In WT mice treated with 2 wk of daily i.p. injections of either 7,8 DHF or deoxygedunin (5 mg/

58 Newborn rat pups received daily i.p. injections of a human-relevant tapering dose of dex

59 eptide (0.3, 1, and 3 muM, given twice daily i.p. for 4 days).

60 Low-dose CP55,940 (0.3 mg/kg daily, i.p. ) suppressed paclitaxel-induced allodynia in WT and

61 High-dose CP55,940 (10 mg/kg daily, i.p.) produced catalepsy in WT mice, which precluded det

62 d-type (WT) mice, LY2828360 (3 mg/kg per day i.p. x 12 days) suppressed chemotherapy-induced neuropat

63 Morphine (10 mg/kg per day i.p. x 12 days) tolerance developed in CB2KO mice but no

64 ministration of LY2828360 (0.1 mg/kg per day i.p. x 12 days) with morphine (10 mg/kg per day x 12 day

65 dered tolerant to morphine (10 mg/kg per day i.p. x 12 days), but it was absent in morphine-tolerant

66 tory of LY2828360 treatment (3 mg/kg per day i.p. x 12 days).

67 AM1710 treatment (5 mg/kg per day x 12 day, i.p.) delayed the development of antinociceptive toleran

68 n of nilotinib at a low dose (0.5 mg/kg/day, i.p.) in tumor-bearing mice not only alleviated muscle w

69 ing-dose morphine regimen (20-100 mg/kg/day, i.p.).

70 e to cocaine (15 mg kg(-1) day(-1) x 5 days, i.p., 1 or 21 day withdrawal), a presynaptic enhancement

71 In contrast, when delivered i.p., tumor reduction is accompanied by dose-dependent s

72 on (ocular DTx), but not systemic depletion (i.p. DTx), of betagal-specific iTregs enhanced experimen

73 rotein E-knockout mice fed a high-fat diet), i.p., 0.13 mumol/day NLS peptide administration for 5 we

74 High-dose i.p. MSC administration to newborn mice exposed to 90% O

75 Histologically, high-dose i.p. MSC administration was associated with alveolar sep

76 ated with saline or cisplatin (20 mg/kg dose i.p.) to induce AKI and were euthanized after 72 hours.

77 Intranasal MSC or lower-dose i.p. administration had no significant effects on lung f

78 n ethanol-induced (1.5 g kg(-1) 20% ethanol, i.p.) conditioned taste aversion (CTA) to saccharin tast

79 on that naive C57BL/6 mice that were exposed i.p. to TCDD showed massive mobilization of myeloid-deri

80 Following i.p. LPS injection, autophagy-deficient mice had higher

81 Following i.p. LPS treatment or systemic bacterial challenge, TARM

82 sweetener, SC-45647, was abolished following i.p. injection of AF-353.

83 mpared to macrophages and B cells, following i.p. immunization.

84 Within hours following i.p. FV3 infection, iValpha6 T cells were specifically r

85 shown efficacy against disease that follows i.p. inoculation of bacteria.

86 7-AAG and rapamycin, enabling a platform for i.p. delivery, sustained multi-drug exposure, and potent

87 e by altering the route of immunization from i.p. to s.c.

88 sion was more efficient from i.n.- than from i.p.-challenged gps, with 17% versus 83% of naive gps su

89 n combination with paclitaxel (12mg/kg given i.p.), ACT induced a strong increase in therapeutic effi

90 nV (100 ug/Kg) was administrated every 48 h (i.p.) for 14 days and several endpoints were evaluated:

91 to the draining lymph node in mice immunized i.p. with alum.

92 More importantly, i.p. administration of LPS induced IL-1beta production i

93 endothelial growth factor, and decreases in i.p. numbers of endothelial and myeloid cells, as well a

94 In contrast to oral infection, i.p. infected CD73(-/-) mice were highly susceptible to

95 were consistent in vivo, because LA injected i.p. into C57BL/6 mice suppressed IL-33-induced plasma c

96 In contrast, ApoE(-/-) mice injected i.p. with Muramyl DiPeptide (MDP) to stimulate NOD2 and

97 now show that Tlr9(-/-) BALB/c mice injected i.p. with TMPD develop more severe autoimmunity than do

98 pancreatitis on PDGs, cerulein was injected i.p., repetitively over 10 weeks, in mice exhibiting obe

99 ryl-hydrocarbon receptor; ITE) were injected i.p. four times at weekly intervals into hTSHR/NOD.H2(h4

100 eically mated C57Bl/6J females were injected i.p. with 50 or 250 mg/kg APAP or phosphate-buffered sal

101 Therefore, C57BL/6 (B6) mice were injected i.p. with VIP, and mRNA, protein, and immunostaining ass

102 antly higher than control mice when injected i.p. with an acetaminophen dose not lethal to the contro

103 received a daily intraperitoneal injection (i.p.) of vehicle control or Delta9-THC (3 mg/kg) from em

104 nt is actually hypervirulent when inoculated i.p. into C3H/HeN mice.

105 Intraperitoneal (i.p.) injections of alphaS fibrils in hemizygous M83 tra

106 /- 22% (n = 5) at 1 h after intraperitoneal (i.p.) injection of glucagon, which is known to rapidly d

107 (E3-E22.5) and received an intraperitoneal (i.p.) injection of 1mg/kg LPS at E10.5.

108 y of intravenous (i.v.) and intraperitoneal (i.p.) paclitaxel combined with S-1, "an oral fluoropyrim

109 Surprisingly, chronic intraperitoneal (i.p.) injection of AD animals with either amylin or pram

110 7-13 improved survival from intraperitoneal (i.p.) and intradermal (i.d.) challenge by L. interrogans

111 Furthermore, intraperitoneal (i.p.) delivery of SSO Ex5 in MMTV-PyMT mice redirects Sm

112 gonist SCH23390 (10 mug/kg, intraperitoneal (i.p.)).

113 In lean mice, intraperitoneal (i.p.) or intracerebroventricular (i.c.v.) administration

114 stablished a mouse model of intraperitoneal (i.p.) A. baumannii infection.

115 y, using the mouse model of intraperitoneal (i.p.) mucin-enhanced A. baumannii infection, we characte

116 enous (i.v.) anti-VCAM-1 or intraperitoneal (i.p.) beta7 blocking antibody administration was used to

117 ) or water before receiving intraperitoneal (i.p.) doses of ketamine or memantine, or infusions of me

118 Upon a single intraperitoneal (i.p.) administration, the optimized formulation effectiv

119 Systemic intraperitoneal (i.p.) injection for 2 weeks significantly reduced CTSS a

120 Here, we demonstrate that intraperitoneal (i.p.) administration of MDP triggered regulatory T cells

121 cationic adjuvants via the intraperitoneal (i.p.) route has been shown to result in strong CD8(+) T-

122 i cysts systemically by the intraperitoneal (i.p.) route.

123 ce were sensitized by three intraperitoneal (i.p.) injections of OVA/alum.

124 other FAAH substrates upon intraperitoneal (i.p.) administration to mice, with peak levels achieved

125 ency of intravenous (i.v.), intraperitoneal (i.p.), and intramuscular (i.m.) routes of injection of a

126 n of the peritoneal cavity (intraperitoneal [i.p.] inoculation).

127 aline or midazolam (2mg/kg, intraperitoneal, i.p.), for 14 days beginning 3 days after burn injury.

128 anoparticles administered intraperitoneally (i.p.) selectively accumulate in tumor-associated macroph

129 i.v.) and S. aureus given intraperitoneally (i.p.) failed to induce mortality.

130 More importantly, intraperitoneally (i.p.) injected PCE efficiently protected mice from S. au

131 with a lethal dose of LPS intraperitoneally (i.p.).

132 ed intranasally (i.n.) or intraperitoneally (i.p.) with 10,000 times the 50% lethal dose (LD50) of gp

133 intravenously (i.v.), or intraperitoneally (i.p.) with Escherichia coli, Klebsiella pneumoniae, Stre

134 ed intranasally (i.n.) or intraperitoneally (i.p.).

135 MRSA pneumonia, mice were intraperitoneally (i.p.) administered 2 or 4 g/kg of ethanol 30 min prior t

136 Male C57BL/6 mice were intraperitoneally (i.p.) injected with a single dose of APAP (350 mg/kg dis

137 amphotericin B (10 mg/kg intraperitoneally [i.p.] once a day [QD]), or caspofungin (2 mg/kg i.p. QD)

138 Intriguingly, i.p. injections of LIF initiated blastocyst implantation

139 ) received injections of recombinant irisin (i.p., 2x/wk).

140 icrog i.c.v.) given before ethanol (1.5 g/kg i.p.) attenuated the sedation and ataxia induced by etha

141 Treatment with inosine (100 mg/kg i.p. at 1, 24 and 48 h following CHI) improved outcome a

142 ansferase-1 inhibitor, oxfenicine (150 mg/kg i.p. daily), resulted in improved whole-body glucose tol

143 6.57% following eight injections of 1 mg/kg i.p. during 39 days, while 3 and 4 showed no such activi

144 iving prolonged treatment with PGB (10 mg/kg i.p. for 21 days), compared with vehicle-treated mice.

145 BNN27 (2,10, and 50 mg/kg i.p. for 7 days) administration 4 weeks post-STZ injecti

146 .] once a day [QD]), or caspofungin (2 mg/kg i.p. QD), and samples were collected on days 7 and 11.

147 lation reward, whereas JJC8-016 (10-30 mg/kg i.p.) did not produce these effects.

148 c administration of R-MOD alone (10-30 mg/kg i.p.) dose-dependently increased locomotor activity and

149 atalepsy induced by haloperidol (0.5-5 mg/kg i.p.) or raclopride (2 mg/kg s.c.).

150 ication of baclofen at a high dose (10 mg/kg i.p.) reduced the power of gamma oscillations and the fr

151 re telemetry experiments, SKA-121 (100 mg/kg i.p.) significantly lowered mean arterial blood pressure

152 lar result was observed when BNN27 (10 mg/kg i.p.) was administered at the onset of diabetes, every o

153 ns by acute haloperidol treatment (0.6 mg/kg i.p.), aripiprazole (1 mg/kg, i.p.) reversed the depolar

154 se to a challenge dose of morphine (10 mg/kg i.p.).

155 Effects of SzV-1287 (20 mg/kg i.p./day) were investigated in the K/BxN serum-transfer

156 administered at doses of 0.003 to 30 mug/kg i.p., it was able to reduce the infarct volume of mice s

157 s not reversed by apomorphine (100-200 ug/kg i.p. or 20 ug/kg i.v.) administration, suggesting that i

158 PLA2 inhibition using SB-435495 at 10 mg/kg (i.p.) effectively suppressed BRB breakdown in streptozot

159 se of 5 mg/kg i.v.) and MTDs of 60-80 mg/kg (i.p.).

160 morphine (10mg/kg, s.c.), midazolam (2mg/kg, i.p.), and chelerythrine chloride (a non-specific PKC in

161 LPS (5mg/kg, i.p.) or saline (0.9% NaCl) was administered to 8-month-

162 induced by glucose administrations (2 g/kg, i.p.) at 0, 1, 3 and 6h post-CCI.

163 b-chronic alcohol treatment (7 d x 2.5 g/kg, i.p.) increased Fgfr1 mRNA expression in the dorsal hipp

164 found that acute alcohol exposure (2.5 g/kg, i.p.) increased the mRNA expression of Fgf2 in the dorsa

165 ode of hyperglycemia (50% glucose at 2 g/kg, i.p.) initiated immediately after CCI was found to signi

166 Longer alcohol exposure (7 d x 2.5 g/kg, i.p.) restricted these increases to the dorsal striatum,

167 Serum from morphine-treated (1 or 10 mg/kg, i.p. every 12 h) or saline-treated mice was collected at

168 A single injection of ketamine (10 mg/kg, i.p.) 24 h prior to testing rescued the CIC stress-induc

169 Ketamine (10 mg/kg, i.p.) administered 2 h, 1 week, or 2 weeks before IS pre

170 zoline, RS45041, and idazoxan, 3.2-75 mg/kg, i.p.) all occasioned > 80% CR4056-associated lever respo

171 nor a subthreshold cocaine dose (1.25 mg/kg, i.p.) alone were sufficient to reinstate drug-seeking be

172 , rats were injected with cocaine (10 mg/kg, i.p.) and assessed for either locomotor sensitization, m

173 asome blocking agents BAY 11-7082 (30 mg/kg, i.p.) and Brilliant Blue G (BBG) (45.5 mg/kg, i.p.) in a

174 reated (6 once-daily injections of 15 mg/kg, i.p.) and drug-naive rats during a test of cue-evoked in

175 CBT (6.4 mg/kg, i.p.) attenuated the observed negative emotional consequ

176 d receptor (KOR) antagonist JDTic (30 mg/kg, i.p.) before CSDS reduced stress effects on both sleep a

177 reated with clozapine-N-oxide (CNO; 3 mg/kg, i.p.) before stage II showed blocking when tested in the

178 AM1710 (10 mg/kg, i.p.) did not precipitate CB1 receptor-mediated withdraw

179 ic and chronic dosing with AM1710 (10 mg/kg, i.p.) did not produce antiallodynic efficacy in the CFA

180 Furthermore, AM1710 (1, 3, 10 mg/kg, i.p.) did not suppress established mechanical allodynia

181 Pretreatment with VK4-116 (5-25 mg/kg, i.p.) dose-dependently inhibited the acquisition and mai

182 er systemic CB1R antagonism (AM251; 3 mg/kg, i.p.) during memory reconsolidation altered (1) subseque

183 ine (40 mg/kg, i.p.) or fluoxetine (5 mg/kg, i.p.) for 21 d.

184 WIN55,212-2, dose-dependently (0.5-2 mg/kg, i.p.) impaired short-term plasticity (STP) and long-term

185 We report in rats that PCP (5 mg/kg, i.p.) impairs a well learned, hippocampus-dependent plac

186 .p.) and Brilliant Blue G (BBG) (45.5 mg/kg, i.p.) in a mouse model of CAR-induced pleurisy.

187 e effects of scopolamine (0.1 and 0.5 mg/kg, i.p.) in male rats.

188 pharmacological stressor yohimbine (2 mg/kg, i.p.) induce reinstatement of nicotine CPP in a norbinal

189 , administration of 3alpha-OH-THP (10 mg/kg, i.p.) on the morning of proestrus improved spatial learn

190 ted daily with either agomelatine (40 mg/kg, i.p.) or fluoxetine (5 mg/kg, i.p.) for 21 d.

191 ce were treated with either Meth (1.2 mg/kg, i.p.) or vehicle in association, dissociation, or absenc

192 ent (0.6 mg/kg i.p.), aripiprazole (1 mg/kg, i.p.) reversed the depolarization block state.

193 ith the A2AR antagonist SCH58261 (0.1 mg/kg, i.p.) reversed the mood and synaptic dysfunction caused

194 nged with lipopolysaccharide (4 or 20 mg/kg, i.p.) to induce endotoxemia with and without recombinant

195 Treatment with ceftriaxone (200 mg/kg, i.p.) upregulated core GLT1 expression and attenuated cu

196 Consistently, cocaine (10 mg/kg, i.p.) was able to induce CPP in Wt but not in NOP (-/-).

197 mg/kg morphine conditioning, CBT (6.4 mg/kg, i.p.) was able to prevent the stress-induced reinstateme

198 Strikingly, URB597 (1 mg/kg, i.p.) was devoid of any deleterious effects in normal co

199 mic administration of propranolol (10 mg/kg, i.p.), a beta-noradrenergic receptor antagonist.

200 rmacological stressor, yohimbine (2.5 mg/kg, i.p.), alone and in combination with cues.

201 imer's mouse model at low dosage (0.1 mg/kg, i.p.), lacking hepatotoxicity even at high dose (3 mg/kg

202 for 1 h, i.v.), pazopanib (30 and100 mg/kg, i.p.), or vandetanib (12.5 and 25 mg/kg, i.p.).

203 inactive metabolite 3beta-OH-THP (10 mg/kg, i.p.), which antagonizes actions of 3alpha-OH-THP.

204 in the NAc in response to cocaine (5 mg/kg, i.p.).

205 a sub-threshold dose of cocaine (7.5 mg/kg, i.p.).

206 the psychomotor stimulant cocaine (10 mg/kg, i.p.).

207 g hepatotoxicity even at high dose (3 mg/kg, i.p.).

208 e after ifenprodil administration (10 mg/kg, i.p.).

209 es and cocaine priming (0, 2.5, 5, 10 mg/kg, i.p.).

210 kg, i.p.), or vandetanib (12.5 and 25 mg/kg, i.p.).

211 10 month-old APP/PS1 mice with 5i (2 mg/kg, i.p., 3 times per week, 4 weeks) rescued learning and me

212 The CB1R antagonist AM251 (1 or 3 mg/kg, i.p., 30-min pretreatment) administered prior to E2 and

213 serial systemic injections of LPS (1 mg/kg, i.p., daily) for 4 consecutive days (LPSx4) consistently

214 en administered repeatedly to rats (6 mg/kg, i.p., four doses), all drugs produce large sustained ele

215 Glu2/3 receptor agonist LY379268 (0.5 mg/kg, i.p., twice daily for 5 days), corrected all the biochem

216 ed with lipopolysaccharide (LPS; 100 mug/kg, i.p.) or vehicle at postnatal day (P)14, and kept until

217 Dexmedetomidine (100 mug/kg, i.p.) prevented and reversed lipopolysaccharide-evoked (

218 versed lipopolysaccharide-evoked (10 mug/kg, i.p.) thermogenesis in free-behaving rats.

219 ry estrogen 17beta-estradiol (E2; 10 mug/kg, i.p., 1-h pretreatment) nor a subthreshold cocaine dose

220 ated with low dose hydrocortisone (2 mg/kg/) i.p. on alternate days.

221 aline or lipopolysaccharide (LPS, 250mug/kg; i.p.), and expression of mRNAs involved in the pathway l

222 st endotoxemia induced by lipopolysaccharide i.p. injection; in these damaged animals, decreased T3 l

223 We immunized mice i.p. with lethally irradiated cells of the colon adenoca

224 CD8(+) T cell (T(CD8+)) ID by injecting mice i.p. with various doses of influenza A virus and assessi

225 Hydrocortisone (0.6 mg/mice i.p.) was administered immediately after hemorrhage.

226 In vivo, mice i.p. injected with miR-133a or miR-146a had marked perit

227 Moreover, SPF WT mice i.p. administered 10 mg/kg MDP were protected against in

228 In wild-type mice, i.p. injection of AF-353 or simple application of the dr

229 In an excisional wound healing model, i.p. MV administration accelerated wound closure through

230 In the mouse model, i.p. administration of 1f, 3f, and 1l derivatives was ef

231 Moreover, i.p. and i.c.v. administrations of SR11935, a brain-pene

232 ound an increased abundance of TAMs in mouse i.p. xenograft models of ovarian cancer that expressed H

233 We used a murine i.p. LPS model of systemic inflammation to mimic sepsis.

234 (45 d) withdrawal from either noncontingent (i.p. injection) or contingent (self-administration) expo

235 The appearance of i.p. injected cells in mesenteric lymph nodes suggests t

236 motor and ICSS threshold-reducing effects of i.p. injection of mephedrone (5.0 mg/kg), MA (0.5-1.0 mg

237 and BALB/c mice were injected with 10 mug of i.p. TDM in light mineral oil (TDM-IP).

238 re significant surge in serum Abeta than one i.p. injection of the peptide.

239 nfection outcome relative to that of s.c. or i.p. inoculation, including the phenotype of infected ce

240 fected cells following i.d., but not s.c. or i.p., inoculation.

241 can be administered drugs by oral gavage or i.p. injection, our model is suitable for achieving accu

242 rCK12a delivered intranasally or i.p. stimulates the expression of CD8alpha, granulysin,

243 (6) cell per pup) were given intranasally or i.p. to newborn severe combined immunodeficiency-beige m

244 Here we show that oral or i.p. tolerization with H. pylori extract prevents the ai

245 ry was later reactivated with either i.v. or i.p. cocaine presentation in the absence of any cue.

246 Garcinol administered after either i.v. or i.p. cocaine reactivation significantly decreased cue-in

247 ompared with mice injected once with i.v. or i.p. TDM.

248 nical studies suggest that intra-peritoneal (i.p.) chemotherapy effectively treats residual EOC after

249 e receptor 1/2 (TLR1/2) ligand Pam3CSK4 plus i.p. injections of anti-CTLA-4 antibody.

250 Rat pups received i.p. injection of either saline or Dex (0.25mg/kg) at 24

251 of anaphylaxis in C57BL/6 mice upon repeated i.p. dosing because of an anti-idiotypic anti-drug Ab im

252 vivo, we treated GILZ KO mice with repeated i.p. injections of low-dose LPS followed by treatment wi

253 Mice that received a single i.p. dose of Pn at the time of infection showed no signs

254 A single i.p. exposure to mannan from Saccharomyces cerevisiae in

255 ear, for metamorphosing axolotls by a single i.p. injection and for axolotl transgenesis using I-SceI

256 While a single i.p. injection of 10 mg/kg (2R,6R)-HNK exerted antidepre

257 We report in this article that a single i.p. injection of 15 mug fatty acid binding protein from

258 A single i.p. injection of either peptide also induces a surge of

259 Therefore, AAV9 was used as a single i.p. injection to deliver LRMIS to test its efficacy in

260 -luc) ovarian cancer xenograft model, single i.p. injections of g-E and g-EAR delayed bioluminescence

261 nse against bacterial infections, we studied i.p. infection by group A Streptococcus (GAS) in wild-ty

262 p.o., and intraperitoneal and subcutaneous (i.p./s.c.) routes.

263 rneal and DLN DCs were depleted by systemic (i.p.) DT treatment.

264 was induced in vivo by carbon tetrachloride i.p. injection or bile duct ligation in wild-type and SE

265 ducing CNS alphaS pathology in M83 mice than i.p. or tail vein injections.

266 Previously, we discovered that i.p. injection of a therapeutic vaccine consisting of ba

267 Here, we found that i.p. injection of human cord blood mononuclear cells inf

268 thotopic ID8-T tumor model, we observed that i.p. delivery of a CXCR4 antagonist-expressing OVV led t

269 Here we report that i.p. administration of siRNA encapsulated by glucan shel

270 The i.p. administration of chemotherapy in ovarian and uteri

271 The i.p. administration of LPS to transgenic mice carrying a

272 The i.p./i.v. TDM (TDM-IVIP) group was compared with mice in

273 val from leptospiral challenge by either the i.p. or i.d. route.

274 in, further inhibited MM tumor growth in the i.p. model.

275 ammation and bone erosion) is similar in the i.p. versus s.c. immunized mice despite the presence of

276 Administration of OVA+CAF09 via the i.p. route did also result in DC activation, whereas no

277 1, BALB/c mice were sensitized to HDM (three i.p. injections) and administered two intranasal HDM exp

278 d reduced cytokine production in response to i.p. and intravitreal muramyl dipeptide (MDP).

279 ent of peripheral macrophages in response to i.p. injections of LPS or live bacteria, suggesting a po

280 cal type C PS (MCPS)-specific Ig response to i.p.-injected intact, heat-killed Neisseria meningitidis

281 -) cells had a membrane phenotype similar to i.p. connective tissue-type MC, but were smaller and hyp

282 uptake by MPhi also was seen in mice treated i.p. with pristane (develop lupus) but not mineral oil (

283 and miR-223 knockout (KO) mice were treated i.p. with 0.5 mug/g body weight anti-Fas antibody Jo2, a

284 Mice that undergo i.p. sensitization and intratracheal challenge with 10(6

285 the lymphoid organs, which takes place upon i.p. immunization, is required for the subsequent activa

286 We have used i.p. injection of activin type IIB receptor (ActRIIB)-mF

287 Using i.p. and intra-articular mouse models of gout-like infla

288 and functional effects of intranasal versus i.p. MSC administration in a rodent model of neonatal lu

289 -(13) C6 ]phenylalanine was administered via i.p. injection.

290 experiments and in vivo mouse labelling via i.p. injection).

291 Human PMP tissue was i.p. grafted and grown into nude mice, then constituted

292 To confirm the role of ANG2 in sepsis, we i.p. injected LPS into C57BL/6J mice, which rapidly deve

293 Eight weeks of thrice-weekly i.p. injections (0.604 and 6.04 mug/kg of recombinant hu

294 ice with cryptolepine (10 mg/Kg body weight, i.p.) resulted in significant inhibition of tumor growth

295 ithout or with 5-Aza (0.5 mg/kg body weight, i.p.), were used.

296 agent bleomycin (BLM; 0.035 U/g body weight, i.p.).

297 When i.p. injected into mice, the 11SB17 strain causes only s

298 ug exposure, the Pr was higher compared with i.p. injected rats.

299 n MRI showed that curcumin (30mg/kg body wt. i.p. from 12-20 weeks) worsened regional brain atrophy.

300 ZIP (8 mg of zymosan, i.p., day 0) was induced in C57BL/6 wild-type (WT), GM-C